Samsung Biologics Achieves Top ESG Rating, Ranking 4th Globally

Samsung Biologics announced that it has earned a top-tier rating in the 2026 ESG Risk Assessment conducted by Sustainalytics, a leading global ESG risk assessment firm.

This achievement signifies the company's dedication to sustainability and corporate governance, as it ranked 4th out of 842 firms in the global pharmaceutical industry sector. The assessment grades companies based on their non-financial risks, with Samsung Biologics scoring 9 points, placing it in the 'Negligible' risk category.

The company has made significant strides in enhancing its management systems across environmental, social, and governance areas. Notable efforts include strengthening environmental management through audits and recycling plans, improving social responsibility with diversity policies, and advancing governance through ethics audits.

John Rim, CEO of Samsung Biologics, stated, "This assessment result reflects our consistent efforts to enhance our ESG risk management system. We will continue responsible management and transparent information disclosure to solidify the trust of global stakeholders."